Sentences with phrase «cancer patients in need»
All donations go directly to The Pink Fund to help cancer patients in need.
http://www.corvetteblogger.com/ Not exact matches
Five years ago, we began collaborating with the University of Pennsylvania and invested in further developing and bringing what we believed would be a paradigm - changing immunocellular therapy to cancer patients in dire need.
The LCP needs to be abandoned in favour of evidence - based medicine in all patient groups including those with terminal cancer.»
In the UK over 16,000 cancer patients are still being denied the drugs they need, an RCF report showed.
There is a general need for more understanding, comfort and expertise on the part of the clergy in their ministry to patients with cancer and to their families.
As you're cooling off this summer, your So Delicious Dairy Free ice cream purchases can help improve the quality of life of cancer patients and families in need through the Brees Dream Foundation!
Ettinger spearheaded the development of SPAMMY ®, a shelf - stable poultry - based product that is fortified with vitamins and minerals, to help prevent childhood malnutrition in Guatemala, and also championed Hormel Vital Cuisine, a brand new product line that meets the specific nutritional needs of patients undergoing treatment for cancer.
Hello I have 16 yrs experience in homehealth ive worked with Dementia, Cancer, Alzheimer's, respite care, hospice, disabled, diabetic patients and special needs.
«While the small - scale study suggests that beta - blockers may reduce the risk of breast cancer returning, more research is needed in this area to determine the effectiveness and safety of the treatment before it can be routinely offered to breast cancer patients.
Challenges highlighted for the year ahead were: Moving forward on piloting flexible sigmoidoscopy bowel screening; a national awareness campaign on bowel cancer; improving diagnostic capacity and productivity; the needs of survivors in different post-treatment phases; providing information to commissioners and providers about patients» experience of care; giving support to tackle issues such as information provision and better communication.
We are currently in the process of developing a nose structure for a patient whose nose has been lost though cancer, using a resorbable plate mesh, rather than titanium which needs to be removed after.»
While further study of larger patient groups with longer follow - up times is needed for this cohort of prostate cancer patients, this study is pivotal in providing evidence for change in practice.»
«We wanted to identify patients at higher risk for amelanotic melanoma in whom we need to look carefully for this cancer type.»
Both of the researchers, who are in their early forties, said they were motivated by the need to give lung cancer patients better options.
«Considering the marked prevalence of both prostate cancer and depression, additional efforts are needed to better understand and ameliorate the decreased survival following prostate cancer diagnosis in the depressed male patient.
Scientists are a step closer to creating blood stem cells that could reduce the need for bone marrow transplants in patients with cancer or blood disorders.
We identified patients with mutations that predict phenomenal outcomes in the disease; this is a group of women with endometrial cancer who won't need the financial, physical or emotional toll of chemotherapy at all — they're patients who are probably cured by surgery alone.
Whether investigating fat cells, immunotherapy or use of the CRISPR - Cas 9 gene - editing tool, which a federal panel recently approved for a select number of patients suffering from three types of cancers, including multiple myeloma, approaches beyond attacking cancer cells are needed in the fight against many cancers.
«It is particularly good news for the large number of affected patients that if they are in good medical care and have survived breast cancer, they do not need to be more worried about deadly heart diseases than women at the same age without breast cancer.»
To ensure that patients can receive all recommended care, we need to recognize the financial burden of cancer and identify patients at risk for financial concerns,» says lead study author Christine M. Veenstra, M.D., M.S.H.P., clinical lecturer in hematology / oncology at the University of Michigan Medical School.
In addition to postoperative A-fib, researchers are studying, for example, what factors can improve outcomes of surgeries performed on weekends; how many rectal cancer operations a hospital needs to perform for the best results; and whether having a trauma department confers a beneficial «halo effect» on patient outcomes across the board.
Medical specialists use similar calculations when giving cancer patients radiation treatments or when they need to estimate how much damage X-rays might produce in DNA.
With over 60 percent of cancer patients utilizing CAM following cancer diagnoses, many academic and community cancer centers are trying to incorporate CAM into conventional cancer care in response to patient needs and demands, he added.
Dr Fiona Blackhall, a senior lecturer in The University of Manchester's Institute of Cancer Sciences and a consultant based at The Christie NHS Foundation Trust — both part of the Manchester Cancer Research Centre — said: «In order to introduce precision medicine, where each cancer patient receives treatment designed to target the genetic makeup of their individual cancer, we need to compare how effective the new targeted treatment is compared to standard chemotherapy treatment.&raquin The University of Manchester's Institute of Cancer Sciences and a consultant based at The Christie NHS Foundation Trust — both part of the Manchester Cancer Research Centre — said: «In order to introduce precision medicine, where each cancer patient receives treatment designed to target the genetic makeup of their individual cancer, we need to compare how effective the new targeted treatment is compared to standard chemotherapy treatment.&Cancer Sciences and a consultant based at The Christie NHS Foundation Trust — both part of the Manchester Cancer Research Centre — said: «In order to introduce precision medicine, where each cancer patient receives treatment designed to target the genetic makeup of their individual cancer, we need to compare how effective the new targeted treatment is compared to standard chemotherapy treatment.&Cancer Research Centre — said: «In order to introduce precision medicine, where each cancer patient receives treatment designed to target the genetic makeup of their individual cancer, we need to compare how effective the new targeted treatment is compared to standard chemotherapy treatment.&raquIn order to introduce precision medicine, where each cancer patient receives treatment designed to target the genetic makeup of their individual cancer, we need to compare how effective the new targeted treatment is compared to standard chemotherapy treatment.&cancer patient receives treatment designed to target the genetic makeup of their individual cancer, we need to compare how effective the new targeted treatment is compared to standard chemotherapy treatment.&cancer, we need to compare how effective the new targeted treatment is compared to standard chemotherapy treatment.»
While this is hopeful news for some patients, more research is needed to further understand not only IL13RA2, but other molecules in breast cancers that may guide diagnosis, prognosis, and ultimately drug development and therapy.
Strahl said, «We think this work will lead to a greater understanding of cancer biology, and open the door to future therapeutic approaches for patients in need of better treatment options.»
But the Cedars - Sinai research suggests that some prostate cancer patients may not receive needed treatments in a timely way.
In the analysis of 23 relevant studies, investigators found that many clinicians are broadly informed about the risk to their patients» fertility brought about by cancer treatment, but many factors hinder the appropriate discussions and referrals needed to provide adequate fertility support to patients of reproductive age.
In some cases such as ovarian cancer, however, drug - free intervals are needed to allow patient recovery from side effects, during which tumors can sometimes begin to grow again or develop resistance to the drugs being used.
Each man needs to work within his own limits, and each has different needs nutritionally,» said Focht, who wants to replicate the research with about 200 prostate cancer patients to see if the findings in this small pilot study hold true.
«In this context, we conducted a study to assess palliative care needs and delivery in patients with advanced, incurable cancer.&raquIn this context, we conducted a study to assess palliative care needs and delivery in patients with advanced, incurable cancer.&raquin patients with advanced, incurable cancer.»
«This is the only system that can grow healthy and cancer cells as if they were just extracted from a patient, and expand them — a million new cells can be grown in a week — as long as needed,» he says.
In 2009, MD Anderson opened what remains the only clinic of its kind at a comprehensive cancer center to address the unmet medical needs of its patients with HCV.
«More research is needed to evaluate the efficacy of this use of a cancer medication to alleviate risk of sudden cardiac death, but we are hopeful that what we observed in mice will translate effectively to humans, providing patients and clinicians with a new paradigm for treating this common and life - threatening illness,» Dudley said.
Currently, cancer is present in one in 10 biopsies ordered by physicians, but all must be analyzed by pathologists to identify the extent and volume of the disease, determine if it has spread and whether the patient has an aggressive or indolent cancer and needs chemotherapy or a less drastic treatment.
This accuracy really shows up in areas such as radiation treatment for cancer, where the dose delivered to the patient's tumour needs to be accurate to within 3 per cent to achieve the best outcome.
«Rucaparib shows clinical benefit in pancreatic cancer patients with BRCA mutation: Results suggest a potential — and much - needed — treatment option for some pancreatic cancer patients.»
However, these studies tended to lack long - term follow - up, evaluated limited patient numbers, had differences in medication after surgery between both groups and lacked the data on cause of death that are needed to evaluate breast cancer - specific survival.
Patients with a history of breast cancer or lymphoma were more than three times as likely to develop heart failure — a condition in which the heart can't pump enough blood to meet the body's needs — compared with a similar group of patients who did not have cancer, according to data being presented at the American College of Cardiology's 67th Annual Scientific Patients with a history of breast cancer or lymphoma were more than three times as likely to develop heart failure — a condition in which the heart can't pump enough blood to meet the body's needs — compared with a similar group of patients who did not have cancer, according to data being presented at the American College of Cardiology's 67th Annual Scientific patients who did not have cancer, according to data being presented at the American College of Cardiology's 67th Annual Scientific Session.
More work is needed to verify that the treatment is broadly successful in all CLL patients and that stray cancer cells don't eventually mutate so that they avoid displaying the molecule targeted by the T cells.
«We urgently need markers to predict which therapies are going to be effective and which will not be effective in individual patients with advanced prostate cancer,» said lead study author Emmanuel Antonarakis, MD, an assistant professor of oncology and urology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Md. «AR - V7 testing may be extremely valuable in guiding treatment decisions for men with hormone - resistant disease in the near future.&cancer,» said lead study author Emmanuel Antonarakis, MD, an assistant professor of oncology and urology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Md. «AR - V7 testing may be extremely valuable in guiding treatment decisions for men with hormone - resistant disease in the near future.&Cancer Center at Johns Hopkins in Baltimore, Md. «AR - V7 testing may be extremely valuable in guiding treatment decisions for men with hormone - resistant disease in the near future.»
Patients undergoing surgery for lung cancer may wait too long to receive treatment, and too many patients skip vital diagnostic steps that are needed to help determine the best possible treatment, according to an article in the August 2015 issue of The Annals of Thoracic Patients undergoing surgery for lung cancer may wait too long to receive treatment, and too many patients skip vital diagnostic steps that are needed to help determine the best possible treatment, according to an article in the August 2015 issue of The Annals of Thoracic patients skip vital diagnostic steps that are needed to help determine the best possible treatment, according to an article in the August 2015 issue of The Annals of Thoracic Surgery.
«More studies are needed to uncover the exact mechanisms involved, but we predict that direct treatment with D4A could prolong survival in some patients with metastatic prostate cancer,» said Dr. Sharifi, «Further studies will also help us develop a potential biomarker profile to predict which patients will respond to D4 — abiraterone.»
With skin cancer, for example, physicians need to look for melanomas on nails, hands and feet, but the researchers found no visuals were provided in any of the textbooks as to what this would look like on dark - skinned patients.
«At the very least, this work should remind clinicians that we need to look beyond family history in treating and counseling pediatric cancer patients and their families.»
The study is «very, very encouraging,» says Clement Ip, a cancer researcher at Roswell Park Cancer Institute in Buffalo, but he and others say more studies are needed to determine how selenium acts on tumors and how it affects a broader spectrum of patcancer researcher at Roswell Park Cancer Institute in Buffalo, but he and others say more studies are needed to determine how selenium acts on tumors and how it affects a broader spectrum of patCancer Institute in Buffalo, but he and others say more studies are needed to determine how selenium acts on tumors and how it affects a broader spectrum of patients.
«There's a great need in cancer patients to be able to quickly and easily assess if a particular treatment is working in order to switch to another if it's not, thus avoiding wasted time, potential side effects and cost,» says Kala Visvanathan, M.D., M.H.S., professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health, professor of oncology at the Johns Hopkins University School of Medicine and director of the Clinical Cancer Genetics Program at the Johns Hopkins Kimmel Cancer Ccancer patients to be able to quickly and easily assess if a particular treatment is working in order to switch to another if it's not, thus avoiding wasted time, potential side effects and cost,» says Kala Visvanathan, M.D., M.H.S., professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health, professor of oncology at the Johns Hopkins University School of Medicine and director of the Clinical Cancer Genetics Program at the Johns Hopkins Kimmel Cancer CCancer Genetics Program at the Johns Hopkins Kimmel Cancer CCancer Center.
«These results confirm that antibiotics - associated dysbiosis might be deleterious in patients treated with immune checkpoint inhibitors, suggesting that an intact gut microbiota is needed to mobilize the immune system regardless of the tumor site,» wrote Lisa Derosa, MD, of Gustave Roussy Cancer Campus, Villejuif, France, and colleagues.
In the Comer Emergency Department, pediatricians, pediatric surgeons, nurses, social workers and other professionals will treat the most complex cases — not only those with traumatic injuries but also patients with all types of severe illnesses who need emergency specialty care, including patients with congenital heart disease, cystic fibrosis, cancer and neurological disorders.
With enthusiasm for cancer immunotherapy mounting thanks to recent successes in the clinic with immune - based cancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer immunotherapy mounting thanks to recent successes in the clinic with immune - based cancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients sCancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients sCancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer treatment and of the need for continued public support for research to bring these treatments to more patients sooner.